Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update

Acorda Therapeutics, Inc. (NASDAQ:ACOR) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 8,100 shares, a decline of 14.7% from the March 15th total of 9,500 shares. Based on an average daily volume of 113,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the company’s shares are short sold.

Acorda Therapeutics Price Performance

Acorda Therapeutics has a 12-month low of $0.61 and a 12-month high of $24.20. The company’s 50-day simple moving average is $11.75 and its 200-day simple moving average is $12.36. The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. purchased a new position in Acorda Therapeutics during the 3rd quarter valued at about $161,000. Deutsche Bank AG purchased a new position in Acorda Therapeutics during the 4th quarter valued at about $26,000. Prudential Financial Inc. purchased a new position in Acorda Therapeutics during the 2nd quarter valued at about $28,000. Geode Capital Management LLC lifted its position in Acorda Therapeutics by 44.8% during the 4th quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 20,948 shares during the period. Finally, Virtu Financial LLC purchased a new position in Acorda Therapeutics during the 2nd quarter valued at about $68,000. 12.71% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Acorda Therapeutics in a research note on Friday. They set a “buy” rating on the stock.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.